Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Emberton

Showing results (451-460 of 475) with videos related to

Pageof 48
Sort By:
European Urology|March 30, 2013
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working GroupCaroline M Moore, Veeru Kasivisvanathan, Scott Eggener, et al.
European Urology|May 7, 2020
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS CohortJoseph M Norris, Lina M Carmona Echeverria, Simon R J Bott, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|February 6, 2022
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year ExperienceDeepika Reddy, Max Peters, Taimur T Shah, et al.
BJU International|February 5, 2025
Refining partial gland ablation for localised prostate cancer: the FALCON projectLara Rodriguez-Sanchez, Xavier Cathelineau, Theo M de Reijke, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
European Radiology|May 24, 2024
PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRIMaarten de Rooij, Clare Allen, Jasper J Twilt, et al.
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Pageof 48

Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
European Urology|March 30, 2013
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working GroupCaroline M Moore, Veeru Kasivisvanathan, Scott Eggener, et al.
European Urology|May 7, 2020
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS CohortJoseph M Norris, Lina M Carmona Echeverria, Simon R J Bott, et al.
European Urology|April 4, 2022
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After RadiotherapyTaimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
European Urology|February 6, 2022
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year ExperienceDeepika Reddy, Max Peters, Taimur T Shah, et al.
BJU International|February 5, 2025
Refining partial gland ablation for localised prostate cancer: the FALCON projectLara Rodriguez-Sanchez, Xavier Cathelineau, Theo M de Reijke, et al.
European Urology|January 21, 2023
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]Taimur T Shah, Abi Kanthabalan, Marjorie Otieno, et al.
The Lancet. Oncology|March 3, 2022
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory studyAlistair D R Grey, Rebecca Scott, Bina Shah, et al.
European Radiology|May 24, 2024
PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRIMaarten de Rooij, Clare Allen, Jasper J Twilt, et al.
BJU International|June 29, 2023
External validation of a risk model predicting failure of salvage focal ablation for prostate cancerAlexander Light, Max Peters, Deepika Reddy, et al.
Contemporary Clinical Trials|April 16, 2026
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trialArchana Gopalakrishnan, Alexander Light, Nikhil Mayor, et al.
Pageof 48